Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome

被引:21
作者
Hadigan, C
Corcoran, C
Piecuch, S
Rodriguez, W
Grinspoon, S
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Combined Program Pediat Gastroenterol & Nutr, Boston, MA 02114 USA
[3] Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1210/jc.85.10.3544
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A novel lipodystrophy syndrome characterized by insulin resistance, hypertriglyceridemia, and fat redistribution has recently been described in human immunodeficiency virus (HIV)-infected men and women. Women with the HIV lipodystrophy syndrome exhibit a marked increase in waist-to-hip ratio and truncal adiposity; however, it is unknown whether androgen levels are increased in these patients. In this study, we assessed androgen levels in female patients with clinical lipodystrophy based on evidence of significant fat redistribution in the trunk, extremities, neck and/or face (LIPO: n = 9; age, 35.7 +/- 1.7 yr; BMI, 24.7 +/- 0.8 kg/m(2)) in comparison with age- and BMI-matched nonlipodystrophic HIV-infected females (NONLIPO: n = 14; age, 37.6 +/- 1.1 yr; BMI, 23.4 +/- 0.6 kg/m(2)) and healthy non-HIV-infected control subjects (C: n = 16; age, 35.8 +/- 0.9 yr; BMI, 23.1 +/- 0.4 kg/m(2)). Fasting insulin, lipid levels, virologic parameters, and regional body composition using dual energy x-ray absorptiometry were also assessed. Total testosterone [ LIFO, 33 +/- 6 ng/dL(1.1 +/- 0.2 nmol/L); NONLIPO, 17 +/- 2 ng/dL (0.6 +/- 0.1 nmol/L); C,23 +/- 2 ng/dL(0.8 +/- 0.1 nmol/L); P < 0.05 LIPO us. C and LIPO vs. NONLIPO] and free testosterone determined by equilibrium dialysis [LIPO, 4.5 +/- 0.9 pg/mL (16 +/- 3 pmol/L); NONLIPO, 1.7 +/- 0.2 pg/mL (6 +/- 1 pmol/L); C, 2.4 +/- 0.2 pg/mL (8 +/- 1 pmol/L); P < 0.05 LIPO us. C and LIPO vs. NONLIPO] were increased in the lipodystrophic patients. Sex hormone-binding globulin levels were not significantly different between LIPO and C, but were significantly lower in the LIPO vs. NONLIPO patients (LIPO 84 +/- 7 vs. NONLIPO 149 +/- 17 nmol/L, P < 0.05). The LH/FSH ratio was significantly increased in the LIPO group compared with the NONLIPO and C subjects (LIPO, 2.0 +/- 0.6; NONLIPO, 1.1 +/- 0.1; C, 0.8 +/- 0.1; P < 0.05 LIPO us. NONLIPO and LIPO vs. C). Body fat distribution was significantly different between LIPO and C subjects. Trunk to extremity fat ratio (1.46 +/- 0.17 vs. 0.75 +/- 0.05, LIPO vs. C, P < 0.05) was increased and extremity to total fat ratio decreased (0.40 +/- 0.03 vs. 0.55 +/- 0.01, LIPO vs. C, P < 0.05). In contrast, fat distribution was not different in the NONLIPO group us. control subjects. Among the HIV-infected patients, free testosterone correlated with percent truncal fat (trunk fat/trunk mass) (r = 0.43, P = 0.04). These data suggest that hyperandrogenemia is another potentially important feature of the HIV-lipodystrophy syndrome in women. Additional studies are necessary to determine the clinical significance of increased androgen levels and the relationship of hyperandrogenism to fat redistribution and insulin resistance in this population of patients.
引用
收藏
页码:3544 / 3550
页数:7
相关论文
共 29 条
  • [1] BARBIERI RL, 1988, FERTIL STERIL, V50, P197
  • [2] Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
    Behrens, G
    Dejam, A
    Schmidt, H
    Balks, HJ
    Brabant, G
    Körner, T
    Stoll, M
    Schmidt, RE
    [J]. AIDS, 1999, 13 (10) : F63 - F70
  • [3] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [4] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [5] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58
  • [6] Lipodystrophy associated with an HIV-protease inhibitor
    Carr, A
    Cooper, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) : 1296 - 1296
  • [7] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    Carr, A
    Samaras, K
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1998, 351 (9119) : 1881 - 1883
  • [8] RISK-FACTORS FOR CORONARY-ARTERY DISEASE IN LEAN AND OBESE WOMEN WITH THE POLYCYSTIC-OVARY-SYNDROME
    CONWAY, GS
    AGRAWAL, R
    BETTERIDGE, DJ
    JACOBS, HS
    [J]. CLINICAL ENDOCRINOLOGY, 1992, 37 (02) : 119 - 125
  • [9] Dong KL, 1999, J ACQ IMMUN DEF SYND, V21, P107
  • [10] Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
    Eagling, VA
    Back, DJ
    Barry, MG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) : 190 - 194